Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Non-Hodgkin 17Neuroblastoma 16Leukemia, Myeloid, Acute 14Leukemia 13Hodgkin Disease 13Central Nervous System Neoplasms 13Small Cell Lung Carcinoma 10Sarcoma 9Brain Neoplasms 9Recurrence 8Medulloblastoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Rhabdoid Tumor 7Multiple Myeloma 7Lymphoma, B-Cell 7Lung Neoplasms 7Burkitt Lymphoma 7Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 6Astrocytoma 6Teratoma 5Ovarian Neoplasms 5Neoplasms, Germ Cell and Embryonal 5Neoplasms 5Glioma 5

Interventions

molibresib 1etoposide phosphate 1Platinum 1Etoposide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic NUT Carcinoma × etoposide phosphate × Clear all
NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡